Blog

Resources for Adjusting to a New Diagnosis of Duchenne

No one is prepared to receive the diagnosis of Duchenne. Most often, parents and caregivers have no prior knowledge of the disease, and information online can be very overwhelming. PPMD has developed a wealth of…

Learn More

WATCH: Family Friday – Reflecting on Adjusting to a New Diagnosis

Family Friday: Reflecting on Adjusting to a New Diagnosis For many of us, self-quarantine is in full swing, and adjusting to a different family structure may be overwhelming. So your PPMD family is launching Family…

Learn More

WATCH: Capricor’s HOPE-2 Final 12-Month Data – Webinar Recording

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to…

Learn More

Santhera Announces Completion of ReveraGen’s Long-Term Extension Study with Vamorolone in Duchenne

PPMD is excited to learn that Santhera Pharmaceuticals and partner ReveraGen Biopharma Inc. have completed a long-term, open-label extension study of 24 months duration with vamorolone in patients with Duchenne. Data from this study in…

Learn More

Duchenne UK and PPMD Announce $1 Million Joint Research Grant Call for Gene Therapy

PPMD is thrilled to announce our partnership with Duchenne UK to launch a joint 2020 Research Grant Call, inviting research proposals for submission and review. Up to $1 million (US) is committed to a project…

Learn More

Register Today for PPMD’s 2020 Annual Conference – Virtual Edition!

Register Today for PPMD’s 2020 Annual Conference – Virtual Edition! Registration is now open for PPMD’s 2020 Virtual Annual Conference! This is an extraordinary time for our global community, as we slowly begin re-emerging from the…

Learn More

ReveraGen to Share Individual Patient Results with Trial Participants

ReveraGen has provided a letter to participants in their vamorolone trial indicating promising results with strength and mobility of patients on drug. Additionally, thanks to a NIH grant, ReveraGen will be sharing individual results with…

Learn More

PPMD Certifies Children’s Health and UT Southwestern Medical Center

Today Parent Project Muscular Dystrophy (PPMD) announced the expansion of our renowned Certified Duchenne Care Center Program (CDCCP) with the certification of the clinic at Children’s Health in Dallas and UT Southwestern Medical Center (Children’s…

Learn More

Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne

Santhera announced today that their SIDEROS study is fully enrolled, with 254 participants ages 10-34 years old. PPMD is excited to learn that this trial is enrolled, allowing the study to continue and enabling Santhera…

Learn More

New Physical Therapy Stretching Video Series from PPMD

PPMD Releases New Physical Therapy Stretching Video Series Last week PPMD shared a blog about the newly published article in Muscle & Nerve summarizing the Contractures in Duchenne and Other Neuromuscular Conditions conference hosted by…

Learn More

Join Our Mailing List